药物评价：雷尼司他——一种用于潜在治疗糖尿病并发症的醛糖还原酶抑制剂。
Drug evaluation: ranirestat--an aldose reductase inhibitor for the potential treatment of diabetic complications.
作者信息
Giannoukakis Nick
机构信息
University of Pittsburgh School of Medicine, Diabetes Institute, 3460 Fifth Avenue, Pittsburgh, PA 15213, USA.
出版信息
Curr Opin Investig Drugs. 2006 Oct;7(10):916-23.
PMID:17086937
Abstract
Ranirestat is an orally available aldose reductase inhibitor under development by Dainippon Sumitomo Pharma Co Ltd (formerly Dainippon Pharmaceutical Co Ltd), Kyorin Pharmaceutical Co Ltd and Eisai Co Ltd for the potential treatment of diabetic complications, such as neuropathy, cataracts, retinopathy and nephropathy. Phase III trials were ongoing in February 2006.
摘要
雷尼司他是一种口服可用的醛糖还原酶抑制剂，由大日本住友制药株式会社（前身为大日本制药株式会社）、杏林制药株式会社和卫材株式会社联合开发，用于潜在治疗糖尿病并发症，如神经病变、白内障、视网膜病变和肾病。2006年2月，该药物正处于III期试验阶段。
Zotero 插件